A detailed history of Legal & General Group PLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 48,670 shares of KYMR stock, worth $2.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,670
Previous 42,485 14.56%
Holding current value
$2.37 Million
Previous $1.71 Million 14.94%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$29.85 - $39.42 $184,622 - $243,812
6,185 Added 14.56%
48,670 $1.45 Million
Q1 2024

May 14, 2024

BUY
$22.9 - $43.57 $93,775 - $178,419
4,095 Added 10.67%
42,485 $1.71 Million
Q4 2023

Feb 15, 2024

BUY
$10.97 - $26.84 $80,980 - $198,132
7,382 Added 23.81%
38,390 $977,000
Q3 2023

Nov 14, 2023

SELL
$13.9 - $23.88 $3,530 - $6,065
-254 Reduced 0.81%
31,008 $431,000
Q2 2023

Aug 14, 2023

SELL
$22.4 - $34.92 $84,067 - $131,054
-3,753 Reduced 10.72%
31,262 $718,000
Q1 2023

May 15, 2023

BUY
$24.84 - $38.75 $46,227 - $72,113
1,861 Added 5.61%
35,015 $1.04 Million
Q4 2022

Feb 14, 2023

BUY
$19.57 - $30.92 $8,297 - $13,110
424 Added 1.3%
33,154 $827,000
Q3 2022

Nov 14, 2022

BUY
$20.91 - $34.27 $84,204 - $138,005
4,027 Added 14.03%
32,730 $713,000
Q2 2022

Aug 22, 2022

BUY
$14.13 - $42.55 $3,645 - $10,977
258 Added 0.91%
28,703 $565,000
Q1 2022

May 16, 2022

BUY
$35.3 - $64.68 $520,498 - $953,706
14,745 Added 107.63%
28,445 $1.2 Million
Q4 2021

Feb 14, 2022

BUY
$49.91 - $65.56 $15,222 - $19,995
305 Added 2.28%
13,700 $870,000
Q3 2021

Nov 15, 2021

BUY
$47.8 - $66.66 $321,072 - $447,755
6,717 Added 100.58%
13,395 $787,000
Q2 2021

Aug 12, 2021

BUY
$31.08 - $51.95 $154,032 - $257,464
4,956 Added 287.8%
6,678 $324,000
Q1 2021

May 17, 2021

SELL
$35.64 - $85.46 $855 - $2,051
-24 Reduced 1.37%
1,722 $67,000
Q4 2020

Feb 12, 2021

BUY
$28.07 - $87.83 $49,010 - $153,351
1,746 New
1,746 $109,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.66B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.